Catalio Capital Management LP Sells 106,100 Shares of Disc Medicine, Inc. $IRON

Catalio Capital Management LP lessened its position in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 49.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 110,427 shares of the company’s stock after selling 106,100 shares during the period. Disc Medicine makes up about 1.6% of Catalio Capital Management LP’s investment portfolio, making the stock its 25th largest position. Catalio Capital Management LP’s holdings in Disc Medicine were worth $8,769,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd bought a new position in Disc Medicine during the 4th quarter worth about $33,000. Aster Capital Management DIFC Ltd bought a new position in Disc Medicine during the 3rd quarter worth about $38,000. KBC Group NV bought a new position in Disc Medicine during the 4th quarter worth about $80,000. Persistent Asset Partners Ltd bought a new position in Disc Medicine during the 4th quarter worth about $141,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after purchasing an additional 490 shares in the last quarter. Institutional investors own 83.70% of the company’s stock.

Insider Activity

In other news, insider William Jacob Savage sold 5,731 shares of the firm’s stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $66.38, for a total value of $380,423.78. Following the completion of the transaction, the insider owned 79,480 shares in the company, valued at $5,275,882.40. This trade represents a 6.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jean M. Franchi sold 6,257 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total value of $433,234.68. Following the completion of the transaction, the chief financial officer owned 64,333 shares of the company’s stock, valued at $4,454,416.92. The trade was a 8.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,388 shares of company stock valued at $841,258 in the last 90 days. 3.76% of the stock is owned by corporate insiders.

Disc Medicine Price Performance

Shares of NASDAQ IRON opened at $70.21 on Thursday. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of -10.61 and a beta of 0.93. The business has a 50-day moving average of $68.44 and a 200-day moving average of $71.93. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, sell-side analysts predict that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IRON shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Wells Fargo & Company increased their target price on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Morgan Stanley increased their target price on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Wedbush restated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $105.80.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.